NCT03836937View on ClinicalTrials.gov

Role of Obeticholic Acid in the Patients of NAFLD With Raised ALT

NACompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 5, 2019

Primary Completion Date

November 30, 2020

Study Completion Date

December 31, 2021

Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
DRUG

Obeticholic acid

Farnesoid X receptor ligand which is a semi synthetic bile acid analogue

Trial Locations (1)

1000

Department of Hepatology, Dhaka

All Listed Sponsors
lead

Sir Salimullah Medical College Mitford Hospital

OTHER_GOV

NCT03836937 - Role of Obeticholic Acid in the Patients of NAFLD With Raised ALT | Biotech Hunter | Biotech Hunter